2024-03-05 09:54:23 ET
Summary
- Takeda wins FDA approval for the first oral treatment for Eosinophilic esophagitis (EoE) in the US.
- The market size for EoE is expected to reach $941.8 million by 2031.
- Takeda's new CFO, Milano Furuta, will focus on growth and increasing shareholder returns.
Editor's note: Seeking Alpha is proud to welcome BioCGT Investor as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click here to find out more » ...
Read the full article on Seeking Alpha
For further details see:
Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds